Thermo Fisher Scientific Inc. $TMO Stock Position Decreased by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 19.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,549 shares of the medical research company’s stock after selling 1,375 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Thermo Fisher Scientific were worth $2,782,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC boosted its position in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after purchasing an additional 988 shares in the last quarter. Revolve Wealth Partners LLC increased its position in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Darwin Wealth Management LLC acquired a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $170,000. Raymond James Financial Inc. increased its position in Thermo Fisher Scientific by 7.4% during the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after buying an additional 53,542 shares during the last quarter. Finally, California State Teachers Retirement System increased its holdings in shares of Thermo Fisher Scientific by 0.4% during the 2nd quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after acquiring an additional 2,262 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the sale, the chief operating officer owned 24,651 shares of the company’s stock, valued at $13,927,815. The trade was a 1.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 26,553 shares of company stock valued at $15,343,589 over the last ninety days. 0.33% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on TMO shares. Jefferies Financial Group reiterated a “buy” rating and issued a $630.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 target price on the stock. Piper Sandler increased their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research note on Monday, July 27th. Barclays boosted their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Finally, Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $619.41.

Thermo Fisher Scientific Trading Up 0.8%

NYSE TMO opened at $598.68 on Tuesday. The stock’s 50-day moving average is $519.74 and its 200-day moving average is $509.70. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $643.99. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The firm has a market cap of $221.36 billion, a P/E ratio of 32.20, a P/E/G ratio of 2.42 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same period last year, the company posted $4.28 EPS. The business’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher received FDA clearance for a multiple myeloma testing platform, strengthening its position in clinical diagnostics and potentially expanding adoption among hospitals, laboratories, and pharmaceutical companies. The development reinforces the company’s broader growth strategy in precision medicine. How Investors Are Reacting To Thermo Fisher Scientific New FDA-Cleared Multiple Myeloma Platform
• Positive Sentiment: Thermo Fisher expects its India customer base to grow 15% to 20% over the next five years as biopharmaceutical research and manufacturing expand in the country. The outlook points to a meaningful long-term international growth opportunity for the company’s instruments, services, and bioproduction businesses. Thermo Fisher Eyes India Customer Growth
• Positive Sentiment: Comparative coverage emphasizes Thermo Fisher’s stronger recent positioning in a potential recovery of pharmaceutical and biotechnology research spending. The company exceeded second-quarter expectations, raised guidance, and reported broad-based demand improvement, factors that can support investor confidence relative to peers such as Danaher. Thermo Fisher vs. Danaher
• Neutral Sentiment: Articles comparing Thermo Fisher with Abbott and Azenta frame the investment decision around diversification, valuation, and exposure to a life-sciences spending recovery. These are investor-perspective pieces rather than new company announcements, so their direct effect on TMO is limited. Abbott vs. Thermo Fisher Thermo Fisher and Azenta Comparison
• Negative Sentiment: CEO Marc Casper and Chief Accounting Officer Joseph Holmes sold shares. Both transactions were disclosed as part of planned trading activity, reducing the likelihood that the sales signal deteriorating business prospects, but insider selling can still create modest short-term sentiment pressure. Thermo Fisher Insider Trading Filing

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.